Shots:

• The P-II (CIBI112A201) study evaluating picankibart (50/100/200mg) vs PBO in a ratio (1:1:1:1:1) in 250 patients with mod. to sev. PsO
• The trial met its 1EPs i.e., 52.0% to 54.9% of patients achieved PASI 90 @16wks.; PASI 75 & 100 were significantly higher over PBO. At 28wks., long-term efficacy was observed with 61.2% to 72.5% of patients who achieved PASI 90; 78.4% to 88.0% in PASI 75, and 40.0% achieved complete skin lesions clearance (PASI 100)
• The therapy was well tolerated with no new safety signals & the overall safety profile was consistent with other IL-23p19 mAbs, a significant increase from baseline in DLQI while 50-200mg picankibart administered q12w or q8w can improve the skin lesions & QoL i.e., significant improvement at a long-dose interval

Ref: PR Newswire | Image: Innovent